Attend

FACILITATE LIVE is proud to present our Orphan Drugs and Rare Diseases Global Congress 2025 Europe. It’s the 23rd  in the series of our Flagship Orphan Drugs & Rare Diseases events. This congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs.

An estimated 300 million people live with rare disease globally, an estimated 36 million in Europe. 80% of rare diseases have a genetic cause, almost 70% of which present in childhood. Collectively, people living with a rare disease represent one of the largest underserved patient communities in the world, with only 5% of known rare diseases having one or more approved treatments. The average time for an accurate diagnosis takes 4·8 years; and about 30% of children with a rare disease die before the age of 5 years. The complex biology and lack of understanding of the natural history of rare diseases makes drug, biologic, and device development in rare diseases very challenging. However, there is limited medical expertise and knowledge about rare diseases, and fewer than 1,000 diseases have even minimal scientific knowledge. Accurate diagnosis and treatment for these diseases has also been teeming with regulatory and logistical barriers. There is an urgent need for a regulatory framework that encourages safe therapeutic innovations and helps ensure their timely access to patients.

According to reports, the global Orphan Drugs Market size has reached a value of USD 214.8 Billion in 2023. looking forward, the market is projected to reach USD 541.3 Billion in 2032, at a CAGR of 1o.5% during the forecast period, 2024-2032. This growth has been driven by several factors such as increasing prevalence of rare diseases exhibited by the growing number of people affected by Rare diseases and rare cancer. Supportive government regulations and policies also helps to drive the market. Increasing R&D initiatives and investments by prominent players and patient advocacy involvement have resulted in major pharmaceutical breakthroughs. The development of blockbuster drugs for the treatment of several rare diseases and advances in genomics and personalised medicines will create opportunities and contribute exponentially to the overall market growth.

The two-day Congress will provide an interactive, cutting edge, and comprehensive discussion and networking format led by key experts with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies, and concepts surrounding orphan drugs and rare diseases.

We look forward to meeting you at the Congress!